منابع مشابه
Oral direct inhibitors of coagulation.
For the first time in 50 years new oral anticoagulants of proven efficacy and with acceptable safety profiles are available for patients with atrial fibrillation and venous thromboembolism. Here is a brief overview of the benefits and possible disadvantages of using these drugs.
متن کاملOral direct factor Xa inhibitors.
Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective, warfarin has numerous limitations, including a variable dose requirement from patient to patient because of differences in dietary vitamin K intake, common genetic polymorphisms, and multiple drug interactions that affect its pharmacodynamics and metabolism. Consequently...
متن کاملOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
BACKGROUND Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly of the leg. It occurs in approximately 1 in 1,000 people. If left untreated, the clot can travel up to the lungs and cause a potentially life-threatening pulmonary embolism (PE). Previously, a DVT was treated with the anticoagulants heparin and vitamin K antagonists. However, two forms of...
متن کاملCoagulation inhibitors in inflammation.
Coagulation is triggered by inflammatory mediators in a number of ways. However, to prevent unwanted clot formation, several natural anticoagulant mechanisms exist, such as the antithrombin-heparin mechanism, the tissue factor pathway inhibitor mechanism and the protein C anticoagulant pathway. This review examines the ways in which these pathways are down-regulated by inflammation, thus limiti...
متن کاملcontinuing education Oral , Direct Factor Xa Inhibitors and Thromboembolic Disorders
pon successful completion of this article, the pharmacist should be able to: 1. List the advantages and disadvantages of currently available anticoagulants. 2. Discuss the role of Factor Xa (FXa) in the coagulation cascade and the rationale for selected FXa inhibition as a target for drug development. 3. Discuss the pharmacology of apixaban and rivaroxaban: mechanism of action, pharmacokinetics...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of the Royal College of Physicians of Edinburgh
سال: 2014
ISSN: 1478-2715,2042-8189
DOI: 10.4997/jrcpe.2014.111